I am a
Home I AM A Search Login

Papers of the Week

2021 May 29

BMC Gastroenterol



Zanubrutinib-induced liver injury: a case report and literature review.


Atallah E, Wijayasiri P, Cianci N, Abdullah K, Mukherjee A, Aithal GP
BMC Gastroenterol. 2021 May 29; 21(1):244.
PMID: 34051727.


Zanubrutinib is a Bruton's tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of hepatotoxicity secondary to zanubrutinib. We report the first case of severe liver injury due to zanubrutinib.